Therapeutic effects of highly purified de-Glycosylated GcMAF in the immunotherapy of patients with chronic diseases

American Journal of Immunology

Volumn 9, Issue 3, 2013, Pages 78-84

  Thyer, Lynda ^a   Ward, Emma ^a   Smith, Rodney ^a   Branca, Jacopo J V ^b   Morucci, Gabriele ^b   Gulisano, Massimo ^b   Noakes, David ^c   Pacini, Stefania ^b  

^a Macro Innovations Ltd   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Immuno Biotech Ltd   (United Kingdom)

Author keywords

Cancer; Complementary medicine; Immunotherapy; Macrophages; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; MACROPHAGE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTISM; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); FEMALE; FIBROMYALGIA; GRANULOCYTE; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOTHERAPY; INFLAMMATORY BREAST CANCER; LYME DISEASE; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SYPHILIS; THERAPY EFFECT;

EID: 84882624445     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2013.78.84     Document Type: Article

References (25)

1. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem., 72: 248-254. PMID: 942051
2. Bradstreet, J.J., E. Vogelaar and L. Thyer, 2012. Initial observations of elevated alpha-Nacetylgalactosaminidase activity associated with autism and observed reductions from GC proteinmacrophage activating factor injections. Autism Insights, 4: 31-38. DOI: 10.4137/AUI.S10485
3. Carruthers, B.M., M.I.V. de Sande, K.L. De Meirleir, N.G. Klimas and G. Broderick et al., 2011. Myalgic encephalomyelitis: International consensus criteria. J. Int. Med., 270: 327-338. DOI: 10.1111/j.1365-2796.2011.02428.x
4. Fabris, A., P. Biagioni, T. Punzi, G. Morucci and M. Gulisano et al., 2012. Role of angiotensinconverting enzyme and vitamin D receptor gene polymorphisms in cancer anorexia-cachexia syndrome. Am. J. Immunol., 8: 65-70. DOI: 10.3844/ajisp.2012.65.70
5. Gregory, K.J., B. Zhao, D.R. Bielenberg, S. Dridi and J. Wu et al., 2010. Vitamin D binding proteinmacrophage activating factor directly inhibits proliferation, migration and uPAR expression of prostate cancer cells. PLoS One, 5: e13428. DOI: 10.1371/journal.pone.0013428
6. Harms, L.R., T.H. Burne, D.W. Eyles and J.J. McGrath, 2011. Vitamin D and the brain. Best Practice Res. Clin. Endocrinol. Metab., 25: 657-669. DOI: 10.1016/j.beem.2011.05.009.
7. Hirota, K., Y. Nakagawa, R. Takeuchi, Y. Uto and H. Hori et al., 2013. Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung cancer in mice. Anticancer Res., 33: 2911-2915. PMID: 23780979
8. Inui, T., D. Kuchiike, K. Kubo, M. Mette and Y. Uto et al., 2013. Clinical Experience of integrative cancer immunotherapy with GcMAF. Anticancer Res., 33: 2917-2919. PMID: 23780980
9. Kalkunte, S., L. Brard, C.O. Granai and N. Swamy, 2005. Inhibition of angiogenesis by vitamin Dbinding protein: Characterization of anti-endothelial activity of DBP-maf. Angiogenesis, 8: 349-360. DOI: 10.1007/s10456-005-9024-7
10. Lapp, C., 2011. IACFS/ME International Conference Summary. Hunter-Hopkins Center, P.A., Charlotte, North Carolina.
11. Meirleir, D., K.L.S.F. Khaiboullina, M. Fremont, J. Hulstaert and A.A. Rizvanov et al., 2013. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins. In Vivo, 27: 177-187. PMID: 23422476
12. Nonaka, K., S. Onizuka, H. Ishibashi, Y. Uto and H. Hori et al., 2012. Vitamin D binding proteinmacrophage activating factor inhibits HCC in SCID mice. J. Surgical Res., 172: 116-122. DOI: 10.1016/j.jss.2010.07.057
13. Nunn, R., 2011. Mere anecdote: Evidence and stories in medicine. J. Eval. Clin. Practice, 17: 920-926. DOI: 10.1111/j.1365-2753.2011.01727.x
14. Pacini, S., G. Morucci, T. Punzi, M. Gulisano and M. Ruggiero et al., 2012a. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. J. Nephrol., 25: 577-581. DOI: 10.5301/jn.5000035
15. Pacini, S., G. Morucci, T. Punzi, M. Gulisano and M. Ruggiero, 2011. Gc protein-derived Macrophage-Activating Factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol. Immunotherapy, 60: 479-485. DOI: 10.1007/s00262-010-0953-7
16. Pacini, S., T. Punzi, G. Morucci, M. Gulisano and M. Ruggiero, 2012b. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res., 32: 45-52. PMID: 22213287
17. Ruggiero, M. and S. Pacini, 2011. The vitamin D axis in chronic kidney disease-state of the art and future perspectives. Eur. Nephrol., 5: 15-19.
18. Thyer, L., E. Ward, R. Smith, M.G. Fiore and S. Magherini et al., 2013. A novel role for a major component of the vitamin D axis: Vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients, 5: 2577-2589. DOI: 10.3390/nu5072577
19. Toyohara, Y., S. Hashitani, H. Kishimoto, K. Noguchi and N. Yamamoto et al., 2011. Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line. Oncol. Lett., 2: 685-691. DOI: 10.3892/ol.2011.306
20. Yamamoto, N., D.D. Lindsay, V.R. Naraparaju, R.A. Ireland and S.N. Popoff, 1994. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J. Immunol., 152: 5100-5107. PMID: 8176226
21. Yamamoto, N., H. Suyama and N. Yamamoto, 2008a. Immunotherapy for prostate cancer with gc proteinderived macrophage-activating factor, GcMAF. Trans. Oncol., 1: 65-72. DOI 10.1593/tlo.08106
22. Yamamoto, N., H. Suyama, H. Nakazato, N. Yamamoto and Y. Koga, 2008b. Immunotherapy of metastatic colorectal cancer with vitamin D-binding proteinderived macrophage-activating factor, GcMAF. Cancer Immunol. Immunotherapy, 57: 1007-1016. DOI: 10.1007/s00262-007-0431-z
23. Yamamoto, N., H. Suyama, N. Yamamoto and N. Ushijima, 2008c. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived Macrophage Activating Factor (GcMAF). Int. J. Cancer, 122: 461-467. DOI: 10.1002/ijc.23107
24. Yamamoto, N., N. Ushijima and Y. Koga, 2009. Immunotherapy of HIV-infected patients with Gc protein-derived Macrophage Activating Factor (GcMAF). J. Med. Virol., 81: 16-26. DOI: 10.1002/jmv.21376
25. Yamamoto, N., V.R. Naraparaju and S.M. Srinivasula, 1995. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res. Hum. Retroviruses, 11: 1373-1378. DOI: 10.1089/aid.1995.11.1373